Pancreatic β-cell regeneration: advances in understanding the genes and signaling pathways involved. by Afelik, Solomon & Rovira, Meritxell
Afelik and Rovira Genome Medicine  (2017) 9:42 
DOI 10.1186/s13073-017-0437-xCOMMENT Open AccessPancreatic β-cell regeneration: advances in
understanding the genes and signaling
pathways involved
Solomon Afelik1* and Meritxell Rovira2*Editorial summary
Recent advances in β-cell regeneration in vivo are
providing insights into the mechanisms involved in
the conversion of distinct pancreatic cell lineages into
β cells. These mechanisms mostly involve reactivation
of the gene encoding the pancreatic endocrine
cell-specifying transcription factor neurogenin-3.bicarbonate-containing secretions to convey acinar-derivedThe promise of pancreatic β-cell regeneration
Diabetes mellitus is a metabolic disorder characterized by
dysfunction, loss, or insufficient mass of β cells. The main
function of β cells is to produce and secrete insulin, the
hormone responsible for the regulation of blood glucose
levels. Type 1 diabetes (T1D) results from autoimmune
destruction of β cells, while type 2 diabetes (T2D) mostly
results from β-cell dysfunction or peripheral tissue resist-
ance to insulin, often culminating in β-cell death. Thus,
both forms of diabetes can benefit from restoration of β-
cell mass. Currently, islet transplantation is the only way
to provide new β cells to diabetic patients, but the scarcity
of compatible cadaveric donors makes this approach
available to only few patients; moreover, it requires life-
long immune suppression [1].
Great progress has been made in the field of in vitro
differentiation of human embryonic and induced pluripo-
tent stem cells toward insulin-producing cells, including
the generation of stem cell-derived β cells from patients
with T1D, leading to an ongoing clinical trial to assess
their safety in humans [2]. Recent advances in studies with
animal models are also beginning to provide compelling
evidence to suggest in vivo β-cell regeneration as a viable
alternative future approach to restoring β-cell mass in* Correspondence: safelik@uic.edu; mrovira@cmrb.eu
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vious studies demonstrating the ability of particular genes
and pathways to induce β-cell neogenesis in vivo from
differentiated adult pancreatic lineages such as acinar
cells, ductal or centroacinar cells, and other endocrine
subtypes [1]. It is worth noting that in early development
all pancreatic lineages, including acinar cells (which
produce digestive enzymes), duct cells (which produce
enzymes into the duodenum), and all the pancreatic endo-
crine subtypes, differentiate from a common pool of multi-
potent pancreatic progenitor cells (MPCs). MPCs become
patterned into acinar progenitor cells and bi-potent ductal/
endocrine progenitor cells. The activation of Ngn3 in this
pool of bi-potent progenitors promotes the differentiation
of all endocrine cells, while Ngn3-negative bi-potent pro-
genitors mature as ductal cells.β-cell regeneration from pancreatic acinar, ductal,
or β-cell lineages requires Ngn3 activation
Various pancreatic regeneration models have been devel-
oped in both mice and rats to study β-cell regeneration
in vivo. These models have been used successfully to re-
program several pancreatic lineages into β cells by genetic
modifications of key transcription factors, highlighting the
prominent role of such genes in β-cell regeneration. These
are often genes involved in β-cell development during em-
bryogenesis. Reactivation of the embryonic pancreatic
endocrine cell-specifying gene Ngn3 appears to be critical
for sustained β-cell regeneration in vivo in most β-cell re-
generation models reported so far [3] (Fig. 1).
While in vivo genetic manipulations are useful for ex-
perimentation, they are not feasible for therapy in
humans. To translate these studies into therapy, it is of
paramount importance to identify signaling pathways or
small molecules that can specifically target key β-cell
reprogramming genes. Recently, several breakthrough
papers have described specific signaling pathways thatle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 Illustration of cellular plasticity between the different pancreatic lineages and the signaling pathways involved in pancreatic β-cell regeneration.
In the regenerative scenarios—acinar to β cell, ductal to β cell, and α to β cell—a transition state involving Ngn3 activation is necessary for the
reprogramming to occur, with the exception of δ to β cell conversion (see [3] and main text for further details). a Acinar cells can be converted into
β cells in vivo by overexpression of Ngn3, Pdx1, and MafA in mice (1). Hyperglycemia can inhibit (shown by a cross) in vivo reprogramming of acinar
cells by Pdx1, Ngn3, and MafA. Furthermore, acinar cells can become β cells in vitro and in vivo after exposure to ciliary neurotrophic factor (CNTF) and
epidermal growth factor (EGF) (2); this regenerative event is dependent on PKA/STAT3 signaling-mediated Ngn3 activation. b Ductal cells can be
reprogrammed into β cells in vivo after genetic deletion of the ubiquitin ligase Fbxw7 (1). Such reprogramming can also be induced in vivo in mice
after treatment with gastrin, EGF, and medium hyperglycemia (2). Interestingly, this ductal to β cell conversion requires a progenitor-like intermediate
state that involves Ngn3 activation. c Similarly, α cells can be converted into β cells by ectopic activation of Pax4 in α cells in the adult pancreas, either
by transgenic overexpression of Pax4 or indirectly by suppressing Arx (1). In a recent report, it was shown that treatment with an artemisinin (for
example, artemether) [9] or long-term administration of gamma-amino butyric acid (GABA) [8] results in robust conversion of α cells to β cells in vitro
and in vivo (2). Both compounds act through the GABAA receptor; artemether treatment increases gephryin protein levels, which potentiates GABAA
receptor signaling while inhibiting mTOR signaling (shown by a cross). Strikingly, both artemisinin and GABA treatments inhibit Arx function or
expression, leading to induction of Pax4 expression, concomitantly inhibiting glucagon secretion and inducing insulin expression. Although the in vivo
α to β switch in itself is independent of Ngn3, the conversion of endogenous α to β cells appears to trigger α-cell neogenesis from ductal cells by
reactivation of Ngn3 in GABA-treated pancreas. d Finally, δ cells can be reprogrammed into β cells in early puberty, although this conversion is
independent of Ngn3 activation
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lineages in vivo.
Notably, Baeyens and colleagues [4] translated know-
ledge gained from in vitro studies to an in vivo mouse
model of β-cell regeneration. This study elegantly
showed that treating alloxan-induced diabetic mice with
epidermal growth factor (EGF) and ciliary neurotrophic
factor (CNTF) was sufficient to stimulate the conversion
of acinar cells into β cells. Moreover, they provided evi-
dence that this regenerative capacity is dependent on
protein kinase A/signal transducer and activator of tran-
scription 3 (PKA/STAT3) signaling, mediating Ngn3 ac-
tivation. Interestingly, a subsequent study has illustrated
how hyperglycemia can inhibit in vivo reprogramming
of acinar cells by the transcription factors Pdx1, Ngn3,
and MafA [5], highlighting the significant role of glucose
levels in the plasticity and β-cell regenerative potential
of the exocrine pancreas. Altogether, these studies pro-
vide critical knowledge for β-cell regeneration from pan-
creatic acinar cells in vivo, with important therapeutic
implications given their vast numbers in the pancreas.
Besides regenerating β cells from pancreatic acinar
cells, there have been recent advances in reprogramming
β cells from pancreatic ducts in vivo. Zhang and co-
workers [6] recently described the effectiveness of
long-term administration of a low dose of the hormone
gastrin (which is produced by the stomach and stimulates
the release of gastric acid that helps to break down and
digest food) and epidermal growth factor (EGF) under
conditions of medium levels of hyperglycemia to repro-
gram Sox9+ ductal cells into β cells in an alloxan-induced
diabetic mouse model. In addition, a recent report demon-
strated the effect of pro-inflammatory cytokines in indu-
cing β-cell neogenesis in adult mouse duct cells by
activating Ngn3 through STAT3 phosphorylation [7], simi-
lar to the requirement of STAT3 signaling for acinar to β-
cell regeneration reported by Baeyens et al. [4]. As EGF
and gastrin are known in other contexts to be involved in
activation of STAT3, it would be interesting to learn if
STAT3-mediated Ngn3 activation plays a role in the ef-
fects reported by Zhang et al. [6].
While these key recent findings connect extracellular
signaling pathways to in vivo β-cell reprogramming of
acinar and ductal cells through Ngn3 activation, an im-
pressive boost to the field of β-cell regeneration also
comes from the discovery of the role of gamma-amino
butyric acid (GABA) receptor signaling in the conver-
sion of α cells to β cells. Two complementary papers
published this year [8, 9] beautifully illustrate how know-
ledge acquired from genetic modification of Arx and
Pax4, key transcription factors involved in α to β cell
conversion, inspired the design of a high-throughput
screen of small molecules to identify compounds that
could either induce Pax4 or inhibit Arx expression in αcell lines in vitro. This led to the identification of the
artemisinin antimalarial drug class (for example, arte-
mether) as hit compounds that induce the conversion of
α to β cells through activation of GABAA receptor sig-
naling in α cells [9]. Indeed, either artemisinin treatment
[9] or long-term administration of GABA [8] results in
robust conversion of α cells to β cells both in vitro and
in vivo. Strikingly, artemisinin or long-term GABA ad-
ministration in vivo inhibits either Arx function or Arx
expression, respectively, leading to induction of Pax4 ex-
pression. Hence, both drugs promote β-cell neogenesis
from α cells in vivo in zebrafish and rodent models of
diabetes, as well as in human islets in vitro. GABA treat-
ment acts via the GABAA receptor in α cells, whereas
artemisinins stabilize the neuronal assembly protein
gephryin in this receptor, thus enhancing GABAA recep-
tor signaling, and consequently inhibiting glucagon
secretion. This suggests that a reduced extracellular con-
centration of glucagon is required for α to β cell conver-
sion mediated by GABA receptor signaling.
In all these regenerative scenarios (Fig. 1)—acinar to β
cell, ductal to β cell, and α to β cell—the transition state
involving Ngn3 activation is necessary for the repro-
gramming to occur. Even though the GABAA-receptor-
signaling-mediated α to β switch per se is independent
of Ngn3, the conversion of endogenous α to β cells ap-
pears to trigger α-cell neogenesis from ductal cells by re-
activation of Ngn3, such that knockdown of Ngn3 in
GABA-treated pancreas exhibits a reduction in α to β
cell conversion [8]. Interestingly, in a recent study by
Cheng and colleagues [10], a fasting-mimicking diet
(FMD) in mice was shown to promote Ngn3-driven
β-cell regeneration through the inhibition of PKA and
mTOR kinases. Also in this study, exposure of healthy
and T1D human islets to low-glucose and low-serum fast-
ing-mimicking medium in vitro was found to significantly
stimulate the secretion of insulin and to induce Sox2
and Ngn3 expression. This may suggest that medium
or low glucose levels play an important role in pan-
creatic lineage reprogramming into β cells through
the activation of Ngn3.
Conclusions
These recent findings suggest that pharmacological
treatment with several compounds or growth factors or
presumably an FMD can promote plasticity and β-cell
regeneration in the pancreas in animal models in vivo.
The signaling pathways involved in such plasticity change
depending on the lineage source of the reprogramming
(acinar, ductal, or α cells). Although there are common re-
quirements for all of them, such as the acquisition of a
transitional progenitor-like state with the activation of
Ngn3, extracellular glucose and glucagon levels might also
play an important role. Thus, these recent findings open
Afelik and Rovira Genome Medicine  (2017) 9:42 Page 4 of 4the door to potential new therapies to restore β-cell mass
in diabetic patients.
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